Crossmark

Synergistic Therapy of Doxorubicin with Cationic Anticancer Peptide L-K6 Reverses Multidrug Resistance in MCF-7/ADR Cancer Cells In Vitro via P-glycoprotein Inhibition

Crossref DOI link: https://doi.org/10.1007/s10989-021-10253-5

Published Online: 2021-07-10

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Che

Huang, Lili

Li, Ruojin

Wang, Ying

Wu, Xiaoxue

Shang, Dejing
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81202448)

National Natural Science Foundation of China (31272314)

Scientific Research Fund of Liaoning Provincial Education Department (L2012382, L201683653)

the Program for Liaoning Innovative Research Team in University (LT2012019)

Natural Science Foundation of Liaoning Department of Science and Technology (20180550306, 2019-ZD-0467)
License Information

Text and Data Mining valid from 2021-07-10

Version of Record valid from 2021-07-10
More Information

Article History

Accepted: 3 July 2021

First Online: 10 July 2021

Declarations

:

: The authors declare no potential conflict of interests.

Document is current

Any future updates will be listed below